Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
409 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ulcerative Colitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2017, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 14, 32, 25, 53, 9 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively. Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Ulcerative Colitis - Overview 7 Ulcerative Colitis - Therapeutics Development 8 Ulcerative Colitis - Therapeutics Assessment 27 Ulcerative Colitis - Companies Involved in Therapeutics Development 41 Ulcerative Colitis - Drug Profiles 84 Ulcerative Colitis - Dormant Projects 375 Ulcerative Colitis - Discontinued Products 381 Ulcerative Colitis - Product Development Milestones 383 Appendix 393
List of Tables
Number of Products under Development for Ulcerative Colitis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Ulcerative Colitis - Pipeline by 4D Pharma PLC, H1 2017 Ulcerative Colitis - Pipeline by AbbVie Inc, H1 2017 Ulcerative Colitis - Pipeline by AbGenomics International Inc, H1 2017 Ulcerative Colitis - Pipeline by Abivax SA, H1 2017 Ulcerative Colitis - Pipeline by Adello Biologics LLC, H1 2017 Ulcerative Colitis - Pipeline by Advinus Therapeutics Ltd, H1 2017 Ulcerative Colitis - Pipeline by Aerpio Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Allergan Plc, H1 2017 Ulcerative Colitis - Pipeline by Am-Pharma BV, H1 2017 Ulcerative Colitis - Pipeline by Amgen Inc, H1 2017 Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H1 2017 Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H1 2017 Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H1 2017 Ulcerative Colitis - Pipeline by Blueberry Therapeutics Ltd, H1 2017 Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017 Ulcerative Colitis - Pipeline by Celgene Corp, H1 2017 Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H1 2017 Ulcerative Colitis - Pipeline by ChironWells GmbH, H1 2017 Ulcerative Colitis - Pipeline by Circle33 LLC, H1 2017 Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H1 2017 Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2017 Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017 Ulcerative Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017 Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H1 2017 Ulcerative Colitis - Pipeline by Eli Lilly and Company, H1 2017 Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H1 2017 Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H1 2017 Ulcerative Colitis - Pipeline by Ferring International Center SA, H1 2017 Ulcerative Colitis - Pipeline by Galapagos NV, H1 2017 Ulcerative Colitis - Pipeline by Genentech Inc, H1 2017 Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H1 2017 Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H1 2017 Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H1 2017 Ulcerative Colitis - Pipeline by Immune Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Inception Sciences Inc, H1 2017 Ulcerative Colitis - Pipeline by InDex Pharmaceuticals AB, H1 2017 Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals Inc, H1 2017 Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd, H1 2017 Ulcerative Colitis - Pipeline by Johnson & Johnson, H1 2017 Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017 Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 Ulcerative Colitis - Pipeline by LG Chem, Ltd., H1 2017 Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H1 2017 Ulcerative Colitis - Pipeline by Lycera Corp, H1 2017 Ulcerative Colitis - Pipeline by Medestea Research & Production SpA, H1 2017 Ulcerative Colitis - Pipeline by Merck & Co Inc, H1 2017 Ulcerative Colitis - Pipeline by Merck KGaA, H1 2017 Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017 Ulcerative Colitis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017 Ulcerative Colitis - Pipeline by Morphotek Inc, H1 2017 Ulcerative Colitis - Pipeline by Ogeda SA, H1 2017 Ulcerative Colitis - Pipeline by Oncobiologics Inc, H1 2017 Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H1 2017 Ulcerative Colitis - Pipeline by Panacea Biotec Ltd, H1 2017 Ulcerative Colitis - Pipeline by Pfizer Inc, H1 2017 Ulcerative Colitis - Pipeline by Principia Biopharma Inc, H1 2017 Ulcerative Colitis - Pipeline by Protab Ltd, H1 2017 Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Protalix BioTherapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Qu Biologics Inc, H1 2017 Ulcerative Colitis - Pipeline by Re-Pharm Ltd, H1 2017 Ulcerative Colitis - Pipeline by Rebiotix Inc, H1 2017 Ulcerative Colitis - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017 Ulcerative Colitis - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017 Ulcerative Colitis - Pipeline by Sandoz International GmbH, H1 2017 Ulcerative Colitis - Pipeline by Sareum Holdings Plc, H1 2017 Ulcerative Colitis - Pipeline by Seres Therapeutics Inc, H1 2017 Ulcerative Colitis - Pipeline by Shire Plc, H1 2017 Ulcerative Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2017 Ulcerative Colitis - Pipeline by Stelic Institute & Co Inc, H1 2017 Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017 Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals Inc, H1 2017 Ulcerative Colitis - Pipeline by Synlogic Inc, H1 2017 Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Ulcerative Colitis - Pipeline by Theravance Biopharma Inc, H1 2017 Ulcerative Colitis - Pipeline by Thetis Pharmaceuticals LLC, H1 2017 Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H1 2017 Ulcerative Colitis - Pipeline by TopiVert Ltd, H1 2017 Ulcerative Colitis - Pipeline by Trino Therapeutics Ltd, H1 2017 Ulcerative Colitis - Pipeline by UCB SA, H1 2017 Ulcerative Colitis - Pipeline by Ventria Bioscience, H1 2017 Ulcerative Colitis - Pipeline by Vivelix Pharmaceuticals Ltd, H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 (Contd..2), H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 (Contd..3), H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 (Contd..4), H1 2017 Ulcerative Colitis - Dormant Projects, H1 2017 (Contd..5), H1 2017 Ulcerative Colitis - Discontinued Products, H1 2017 Ulcerative Colitis - Discontinued Products, H1 2017 (Contd..1), H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
